Skip to main content
TipRanks
Go Ultimate75% OFF

Globe Life (GL) AI Stock Analysis

661 Followers
GL

Globe Life

(NYSE:GL)

Select Model
Rating:69Neutral
Price Target:$177.00▲(10.12% Upside)
Action:reiterated
Date:11/05/26

The score is supported primarily by strong financial quality (cash generation, ROE, and a healthy balance sheet) and reasonable valuation (low P/E). It is held back by weaker technical momentum and earnings-call risks tied to near-term margin volatility (health/Evri and claims disruption) and the reduced 2026 EPS guidance.

Positive Factors
Premium GrowthBroad premium growth supports recurring revenue and demonstrates demand across both life and health products. The strong health trajectory and continued life expansion diversify growth drivers, while management’s 2027 outlook suggests the momentum is expected to persist beyond one reporting period.
Negative Factors
Margin PressureLower health margins and weaker trailing profitability indicate that revenue growth is not translating into earnings at the prior level of efficiency. If margin pressure persists, it could constrain earnings growth, reduce cash available for capital returns, and make future guidance more difficult to achieve.

Globe Life Key Performance Indicators (KPIs)

Insurance Premium Revenue by SegmentShows the distribution of premium income across different insurance segments, highlighting which areas drive the most revenue and indicating potential growth or risk in specific markets.

$0.00$250.00M$500.00M$750.00M$1.00B$1.25BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Globe Life’s premium growth is increasingly driven by Health rather than Life: Life remains the larger, steady cash cow with slow, consistent gains, while Health has accelerated materially in the last few quarters and is shifting the premium mix. Annuities are immaterial. For investors that means topline momentum, but also greater exposure to health-claims volatility and regulatory/price-sensitivity risk—monitor underwriting margins and loss trends in upcoming reports to see if faster Health growth is profitable or simply volume expansion.

Data provided by:The Fly

Globe Life (GL) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%50%GL+22.91%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$12.13B
Dividend Yield
0.78%
Average Volume (3M)
499.70K
Price to Earnings (P/E)
10.6
Beta (1Y)
0.43
Revenue Growth
5.62%
EPS Growth
8.90%
Country
US
Employees
3,695
Sector
Financial
Sector Strength
68
Industry
Insurance - Life

Globe Life Business Overview & Revenue Model

Company Description

Globe Life Inc. delivers diverse life insurance and supplementary health coverage, alongside annuity products, targeting households in the lower-middle to middle-income brackets throughout the United States. The company's operations are structured in...

How the Company Makes Money

Globe Life makes money primarily by underwriting insurance and investing the premiums it collects. (1) Premium revenue: The core revenue stream is recurring premiums paid by policyholders for life and supplemental health policies. Premiums are priced...

Globe Life Earnings Call Summary

Earnings Call Date:Oct 21, 2026(Q3-2026)|% Change Since:-5.24%|Next Earnings Date:Feb 10, 2027
Earnings Call SentimentPositive

The call was broadly constructive. Management reported growth in operating income, total and health premiums, book value, sales activity, investment income, capital flexibility, and shareholder returns, while also outlining favorable claims experience, AI initiatives, Bermuda-related cash flow opportunities, and 2027 growth guidance. These positives were partially offset by a 2% decline in GAAP net income, lower 2026 EPS guidance, direct-to-consumer and American Income recruiting challenges, lower life and health margin metrics, CMS-related claims disruption, and significant volatility and losses at the early-stage Evri business.

Positive Updates

Operating Income and Book Value Growth
Third-quarter net operating income increased 1% year over year to $379 million, or $4.84 per share, compared with $4.81 per share a year ago. Book value per share increased 23% to $85.35 on a GAAP-reported basis and increased 11% to $103.62 excluding AOCI. Return on equity through September 30 was 19.7% on a GAAP-reported basis and 15.9% excluding AOCI.

Negative Updates

GAAP Net Income Decline
Third-quarter net income decreased 2% year over year to $361 million, or $4.62 per share, compared with $4.73 per share a year ago.

Company Guidance

For full year 2026, Globe Life expects total premium revenue growth to be around 6.5%, life premium revenue growth between 2.5% to 2.75%, life underwriting margin of 44% to 45% of premium, health premium revenue growth around 15%, health underwriting margin growth in the range of 4.0% to 4.5%, health underwriting margin of 22% to 24% of premium, administrative expenses at approximately 7.3% of premium, American Income average producing agent count down around 5%, Liberty National up around 9%, Family Heritage up around 5%, net life sales approximately flat at American Income, up around 10% at Liberty National and down around 9% at Direct to Consumer, and net health sales down around 7% at Liberty National, up approximately 10% at Family Heritage and up around 45% at United American; net operating earnings per diluted share are expected in the range of $15.35 to $15.65, normalized EPS growth approximately 8%, net investment income growth around 4.5%, required interest growth around 3.5%, excess investment income growth of 10% to 11%, average yield on total long term investments approximately 5.51%, and share repurchases in the range of $725 million to $775 million. For full year 2027, the company expects net operating earnings per diluted share in the range of $16.10 to $17.10, representing an increase of 7% at the midpoint, total premium revenue growth of 6% to 8%, life premium revenue growth of 4%, health premium revenue growth of 13% to 15%, life underwriting margin of 42% to 45% of premium, health underwriting margin of 20% to 24%, health underwriting margin dollar growth of 7% to 9%, net investment income growth in the range of 2.5% to 3.5%, required interest growth in the range of 3.5% to 4.0%, average yield on total long term investments between 5.50% to 5.55%, parent excess cash flows approximately $850 million to $950 million, and a cash conversion ratio in the range of 70% to 75% of net operating income; 2027 sales growth is expected to be mid- to high-single-digit at American Income, low double digit at Liberty National and low single digit at Direct to Consumer for net life sales, and low double digit at Liberty National and Family Heritage and high single digit at United American for net health sales.

Globe Life Financial Statement Overview

Summary

Fundamentals are solid: steady multi-year revenue growth, consistently strong ROE, and robust cash generation with free cash flow tracking close to net income. The main risk is the noted TTM profitability step-down versus 2025, which could signal near-term margin pressure despite strong growth.

Income Statement

74Positive

Balance Sheet

80Positive

Cash Flow

83Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue6.28B6.00B5.78B5.45B5.23B5.12B
Gross Profit1.33B2.00B1.87B1.64B1.54B1.69B
EBITDA596.82M1.59B1.45B1.30B1.19B1.36B
Net Income1.19B1.16B1.07B970.75M894.39M1.03B
Balance Sheet
Total Assets30.57B30.81B29.08B28.05B25.99B29.77B
Cash, Cash Equivalents and Short-Term Investments17.23B18.05B17.41B18.06B16.71B21.47B
Total Debt2.99B2.63B2.74B2.12B2.08B2.03B
Total Liabilities23.95B24.84B23.77B23.56B22.04B21.13B
Stockholders Equity6.62B5.97B5.31B4.49B3.95B8.64B
Cash Flow
Free Cash Flow1.33B1.25B1.33B1.43B1.39B1.40B
Operating Cash Flow1.41B1.40B1.40B1.48B1.42B1.44B
Investing Cash Flow-946.00M-643.62M-641.52M-926.15M-943.01M-913.37M
Financing Cash Flow-515.51M-768.05M-715.84M-541.49M-492.45M-523.60M

Globe Life Technical Analysis

Technical Analysis SentimentNegative
Last Price160.74

Price Trends

50DMA165.53Negative
100DMA171.84Negative
200DMA160.31Positive

Market Momentum

MACD-1.46Negative
RSI46.54Neutral
STOCH50.38Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GL, the sentiment is Negative. The current price of 160.74 is below the 20-day moving average (MA) of 161.31, below the 50-day MA of 165.53, and above the 200-day MA of 160.31, indicating a neutral trend. The MACD of -1.46 indicates Negative momentum. The RSI at 46.54 is Neutral, neither overbought nor oversold. The STOCH value of 50.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GL.

Globe Life Risk Analysis

Globe Life disclosed 24 risk factors in its most recent earnings report. Globe Life reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our investment portfolio contains certain alternative investments that may be illiquid and volatile, which could negatively affect our investment income and liquidity.Q4, 2025
2.Recent volatility in the trading price of our common stock has and can be expected to result in securities class action litigation.Q4, 2024
3.We have become subject to, and may in the future be subject to, short selling strategies driving down the market price of our common stock.Q4, 2024

Globe Life Peers Comparison

Overall Rating

UnderperformOutperform
Sector (68)

Financial Indicators

GL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PRIPRI86Outperform$8.86B11.5730.97%1.58%7.93%16.30%
CNOCNO74Outperform$5.25B12.8316.62%1.22%2.47%53.14%
AFLAFL73Outperform$62.57B18.6611.85%1.89%-6.22%-10.65%
GLGL69Neutral$12.08B10.5619.09%0.78%5.62%8.90%
Sector *68Neutral$18.00B11.429.92%3.81%9.73%1.22%
SNFCASNFCA61Neutral$244.72M6.048.21%―-4.19%103.64%
UNMUNM51Neutral$12.26B56.622.23%2.42%-4.15%-72.51%

* Financial Sector Average

Performance Comparison

0%20%40%GLAFLCNOPRISNFCAUNMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GLGlobe Life Inc.160.7430.3823.30%
AFLAFLAC Incorporated127.6117.6416.04%
CNOCNO Financial Group57.4718.3546.90%
PRIPrimerica293.3942.6317.00%
SNFCASecurity National Financial9.001.6121.79%
UNMUnum Group79.845.677.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026